drugset / Trial / NCT00124943
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following angioplasty for in-stent restenosis.
Timeline
- Start
- 2005-07
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 10 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 22 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 35 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 45 mg/m2 | Other |